Suzanne Bruhn
Director/Board Member at MIND MEDICINE (MINDMED) INC.
Net worth: 640 949 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ivana Magovcevic-Liebisch | M | 55 | 6 years | |
| Gregg Lapointe | M | 65 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 10 years |
| Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 13 years |
| Gary Lyons | M | 73 | 10 years | |
| Chris Cline | M | 40 | 10 years | |
| Bernard Coulie | M | 58 | 8 years | |
| Miri Wernli | M | 71 | 4 years | |
| Richard Jack | M | - |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 10 years |
| Ho Young Huh | M | 54 | 7 years | |
| Carol Vallone | F | 67 | 3 years | |
| Eric Dube | M | 51 | 5 years | |
| Jeffrey Meckler | M | 57 | 10 years | |
| Robert Barrow | M | 35 | 3 years | |
| Gerhard Koenig | M | 63 | 4 years | |
| Samantha Haeberlein | M | - | 1 years | |
| Barbara Tate | M | - |
Tiaki Therapeutics, Inc.
 Tiaki Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tiaki Therapeutics, Inc. develops novel therapeutics for Alzheimer's disease. The company was founded by Barbara Tate and is headquartered in Cambridge, MA. | - |
| Sandra E. Poole | F | 60 | 5 years | |
| Smital Shah | F | 48 | 5 years | |
| Bill DeGrado | M | - | 9 years | |
| Stefan Vitorovic | M | 39 | 3 years | |
| Monica Sandberg | M | - | 5 years | |
| Sandra Calvin | F | 59 | 10 years | |
| Mike Ouimette | M | 51 | 4 years | |
| Christopher Keenan | M | - | 4 years | |
| Katharine Knobil | M | 60 | 2 years | |
| Carole Abel | F | - | - | |
| John Curnutte | M | 72 | 7 years | |
| David Pyott | M | 70 | 3 years | |
| Mary Jeka | F | - |
EMPath
 EMPath Miscellaneous Commercial ServicesCommercial Services EMPath provides nonprofit programs for women. The non-profit company is based in Boston, MA. | 14 years |
| Darren Cline | M | 59 | 1 years | |
| Roy Baynes | M | 69 | 8 years | |
| Elizabeth Reed | F | 53 | 7 years | |
| Mary Thistle | F | 64 | 2 years | |
| Cheryl Blanchard | M | 59 | 4 years | |
| Tim Coughlin | M | 57 | 9 years | |
| Andreas Krebs | M | 65 | 3 years | |
| June Almenoff | M | 67 | 3 years | |
| Gilla Kaplan | M | 76 | 4 years | |
| Gayle Crowell | F | 73 | 4 years | |
| Mark Sullivan | M | 52 | 1 years | |
| Roger Crystal | M | 47 | 2 years | |
| Ruth Williams-Brinkley | F | 72 | 3 years | |
| Bruce Booth | M | 49 | 4 years | |
| Kim Lee | M | - | 10 years | |
| Paul Hoelscher | M | 59 | 8 years | |
| John Orwin | M | 62 | 7 years | |
| Ron Squarer | M | 57 | 7 years | |
| Thomas McCourt | M | 66 | 1 years | |
| Dean Sheppard | M | - | 9 years | |
| April Effort | F | - | - | |
| Park Guo | M | - | - | |
| Charlotte Smith | F | - | - | |
| Katerina Leftheris | F | - | - | |
| Rik Derynck | M | - | - | |
| Hans Hull | M | 49 | 8 years | |
| Peter Mack | M | - | 3 years | |
| Casey Logan | M | 52 | 6 years | |
| Hal Chapman | M | - | 9 years | |
| Daniel Karlin | M | 44 | 3 years | |
| Bill Rote | M | 61 | 7 years | |
| Naomi Eichenbaum | F | - | - | |
| Pam Meneses | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christopher Starr | M | 71 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 10 years |
| Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 years |
| Stephen Aselage | M | 73 | 10 years | |
| Uli Alf Hacksell | M | 74 | 5 years | |
| Julie Smith | F | 53 | - | |
| Graham Hetherington | M | 65 | 6 years | |
| Franz Hefti | M | 76 |
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 3 years |
| Michael Patrick Smith | M | 55 | 1 years | |
| Simon Pedder | M | 63 | 2 years | |
| Kim Tsuchimoto | F | 61 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 9 years |
| James Bowling | M | 56 | 10 years | |
| Erich Sager | M | 66 | 6 years | |
| Schond Greenway | M | 52 | 3 years | |
| Jason Lettmann | M | 46 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 6 years |
| Michael Dennis Price | M | 66 | 3 years | |
| Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 years |
| Jeffrey Poulton | M | 56 | 14 years | |
| Angus Russell | M | 68 | 14 years | |
| Llew Keltner | M | 74 | 7 years | |
| Susan Kilsby | F | 65 | 8 years | |
| Dominick Colangelo | M | 60 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 4 years |
| Sol Barer | M | 76 | 1 years | |
| Gregory Perry | M | 63 | 1 years | |
| Cortney Caudill | F | - | 4 years | |
| Phillip Gutry | M | 50 | 6 years | |
| Souheil Salah | M | - | 16 years | |
| Maxim Jacobs | M | - | - | |
| Illya Keith Maher | M | 56 | 1 years | |
| Tatjana Anni Hilde May | F | 58 | - | |
| Paul McBarron | M | 63 | 5 years | |
| Cynthia Hu | M | 54 | 2 years | |
| V. Lawlis | M | 72 | 5 years | |
| David John Kappler | M | 76 | 12 years | |
| Brigid Makes | F | 68 | 4 years | |
| Raymond Anderson | M | 82 | 7 years | |
| Charles Homcy | M | 75 | 7 years | |
| Keith W. Schmidt | M | 74 | 1 years | |
| Ian Karp | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 76 | 76.00% |
| Canada | 15 | 15.00% |
| Ireland | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Suzanne Bruhn
- Personal Network
